

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002 PTO SB 08A (08-00)
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 17

Complete if Known

Application Number 09/545,139
Filing Date April 7, 2000
First Named Inventor D'Amato et al.
Group Art Unit 1614
Examiner Name J. Goldberg
Attorney Docket Number 05213-0650 43170-23681

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>L</i>	AA	2,830,991	04/15/58	Keller, et al.	260	281	
<i>g</i>	AB	3,560,495	02/02/71	Frankus, E.	260	247.1	
<i>g</i>	AC	3,563,986	02/16/71	Frankus, E.	260	247.1	
<i>g</i>	AD	3,625,946	12/07/71	Heinrich, et al.	260	281	
<i>g</i>	AE	3,705,162	12/05/72	Graudums, et al.	260	281	
<i>g</i>	AF	4,552,888	11/12/85	Koppel, et al.	514	474	
<i>g</i>	AG	4,994,443	02/19/91	Folkman, et al.	514	56	
<i>g</i>	AH	5,001,116	03/19/91	Folkman, et al.	514	56	
<i>g</i>	AI	5,021,404	06/04/91	Folkman, et al.	514	26	
<i>g</i>	AJ	5,134,127	07/28/92	Stella, et al.	514	058	

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.	
<i>g</i>	AK	1,182,709	03/04/70	Austria	Kwizda, R.		
<i>g</i>	AL	58-131978	08/06/83	Japan			X
<i>g</i>	AM	63-119500	05/24/88	Japan			X
<i>g</i>	AN	0325199	07/26/89	EPO	Takeda Chemical Industries, LTD		
<i>g</i>	AO	0357061	03/07/90	EPO	Takeda Chemical Industries, LTD		
<i>g</i>	AP	WO 91/10424	07/25/91	PCT	Northwestern University		
<i>g</i>	AQ	WO 92/14455	09/03/92	PCT	The Rockefeller University		
<i>g</i>	AR	WO 92/18496	10/29/92	PCT	Grünenthal GMBH		X
<i>g</i>	AS	WO 94/20085	09/15/94	PCT	Children's Hospital Medical Center		
<i>g</i>	AT	WO 95/04533	02/16/95	PCT	Andrulis Pharmaceuticals Corporation		
<i>g</i>	AU	WO 00/55134	09/21/00	PCT	Celgene Corporation		

EXAMINER

DATE CONSIDERED

8/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2001 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 17

Application Number 09/545,139
Filing Date April 7, 2000
First Named Inventor D'Amato et al.
Group Art Unit 1614
Examiner Name J. Goldberg
Attorney Docket Number 05213-0650 43176-19681

RECEIVED
AUG 03 2001
FBI CENTER 1621/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
g	BA	5,385,901	01/31/95	Kaplan, et al.	514	231.5	
g	BB	5,399,363	03/21/95	Liversidge, et al.	424	490	
g	BC	5,405,855	04/11/95	Andrulis, Jr.	514	323	
g	BD	5,434,170	07/18/95	Andrulis, Jr.	514	323	
g	BE	5,443,824	08/22/95	Piacquadio	424	78.02	
g	BF	5,502,066	03/26/96	Heinemann	514	360	
g	BG	5,605,684	02/25/97	Piacquadio	424	78.02	
g	BH	5,605,914	02/25/97	Muller	514	339	
g	BI	5,643,915	07/01/97	Andrulis, Jr. et al.	514	279	
g	BJ	5,654,312	08/05/97	Andrulis, Jr. et al.	514	279	
g	BK	5,679,696	10/21/97	Fenton et al.	514	354	
g	BL	5,731,325	03/24/98	Andrulis, Jr. et al.	514	323	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


g	BM	Algire, G. H., "Vascular Reactions of Normal and Malignant tissues In Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants", <i>J. Nat'l Canc. Inst.</i> , pp. 73-85 (1945)
g	BN	Allegri, A., "Confermata l'inefficacia della Talidomide Nella Terapia dei Tumori", <i>Gazzetta Medica Italiana</i> , pp. 124-127 (1964)
g	BO	Ambs, S. et al., "Interactive Effects of Nitric Oxide and the p53 Tumor Suppressor Gene in Carcinogenesis and Tumor Progression", <i>The FASEB Journal</i> , Vol. 11, pp. 443-448 (1997)
g	BP	Apt, W. "Effect of Thalidomide on the Course of Experimental Chagas' Disease", <i>BOI. Chil. Parasitol.</i> , Vol. 20, No. 3, pp. 84-86 (1965)
g	BQ	Aronson, et al., "Thalidomide-Induced Peripheral Neuropathy. Effect of Serum Factor on Nerve Cultures", <i>Arch. Dermatol.</i> , Vol. 120, No. 11, pp. 1466-1470 (1984)
g	BR	Bach, et al., "Studies on the Possible Anti-Neoplastic Effect of Thalidomide", <i>ACTA Pathologica ET Microbiologica Scandinavica</i> , Vol. 59, pp. 491-499 (1963)
g	BS	Bach, et al., "Thalidomide in Cancer Chemotherapy", <i>The Lancet</i> , Vol. 1, p. 1271 (1963)
g	BT	Bahmer, F.A., "Therapie bei lymphozytischer Infiltration", <i>Der Hautarzt</i> , Vol. 43, p. 663 (1992)
g	BU	Balabanova, et al., "Lupus Erythematosus Hypertrophicus et Profundus", <i>Z. Hautkr.</i> , Vol. 67, No. 9, pp. 812-815 (1992)

EXAMINER

DATE CONSIDERED

8/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002 OMB 0651-0087
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

RECEIVED
AUG 03 2001
TECHNICAL CENTER 1600/2980

Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/545,139
		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
Sheet 3 of 17		Attorney Docket Number	05213-0650 43170-2981

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Barnes, et al., "Tumor Necrosis Factor Production in Patients with Leprosy", <i>Infection and Immunity</i> , Vol. 60, No. 4, pp. 1441-1446 (1992)
CB	Barnhill, et al., "Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various Other Conditions", <i>J. Am. Acad. Dermatol.</i> , Vol. 7, No. 3, pp. 317-323 (1982)
CC	Barnhill, R. et al., "Studies on the Anti-inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytes and Monocytes", <i>J. Am. Acad. Derm.</i> , Vol. 11, No. 5, Part 1, pp. 814-819 (1984)
CD	Barriere, H., "Traitement par la thalidomide", <i>La Presse Medicale</i> , Vol. 12, No. 15, pp. 963 (1983)
CE	Bazzoli, et al., "The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt", <i>J. Embryol. Exp. Morph.</i> , Vol. 41, pp. 125-135 (1977)
CF	Beck, Jr. et al., "Vascular Development: Cellular and Molecular Regulation", <i>The FASEB Journal</i> , Vol. 11, pp. 365-374 (1997)
CG	Beccerica, E., "L'approccio terapeutico al paziente anziano con artrite reumatoide", <i>Clin. Ter.</i> , Vol. 122, pp. 289-298 (1987)
CH	Belaube, P. et al., "Should Thalidomide be Rehabilitated?", <i>Sem. Hop. Paris</i> , Vol. 59, No. 45, pp. 3101-3104 (1983)
CI	Bensinger, W.I., "Supportive Care in Marrow Transplantation", <i>Curr. Opin. Oncol.</i> , Vol. 4, No. 4, pp. 614-623 (1992)
CJ	Bernal, et al., "Cellular Immune Effects of Thalidomide in Actinic Prurigo", <i>Int'l. J. of Dermat.</i> , Vol. 31, No. 8, pp. 599-600 (1992)
CK	Blair, R. et al., "Human Mast Cells Stimulate Vascular Tube Formation", <i>Journal of Clinical Investigation</i> , Vol. 99, No. 11, pp. 2691-2700 (1997)
CL	Blaschke, V. et al., "Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere", <i>Arzneimittel Forsch./Drug Res.</i> , Vol. 29, No. II, pp. 1640-1642 (1979)
CM	Bonifacino, J. et al., "A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum", <i>Science</i> , Vol. 2, pp. 79-80 (1990)
CN	Bonnetblanc, et al., "Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study", <i>Dermatology</i> , Vol. 193, No. 4, pp. 321-323 (1996)
CO	Boodman, S.G., "Questions About a Popular Prenatal Test", <i>The Washington Post</i> (1992)
CP	Bowers, et al., "Effect of Thalidomide on Orogenital Ulceration", <i>Br. Med. Journ.</i> , Vol. 287, No. 6395, pp. 799-800 (1983)
CQ	Boylen, J.B. et al., "Teratogenic Effects of Thalidomide and its Metabolites on the Developing Chick Embryo", <i>Canadian Journal of Biochemistry</i> , Vol. 42, pp. 35-42 (1964)
CR	Braun, et al., "Thalidomide Metabolite Inhibits Tumor Cell Attachment to Concanavalin A Coated Surfaces", <i>Biochem. Biophys. Res. Comm.</i> , Vol. 98, No. 4, pp. 1029-1034 (1981)
CS	Brem, H. et al., "Interstitial Chemotherapy with Drug Polymer Implants for the Treatment of Recurrent Gliomas", <i>J. Neurosurg.</i> , Vol. 74, pp. 441-446 (1991)
CT	Bressler, S. et al., "Clinicopathologic Correlation of Occult Choroidal Neovascularization in Age-Related Macular Degeneration", <i>Arch. Ophthalmol.</i> , Vol. 110, p. 827 (1992)
CU	Brodthagen, H., "Significant Response of Oral Aphthosis to Thalidomide Treatment", <i>J. Am. Acad. Dermatol.</i> , Vol. 13, No. 3, p. 509 (1985)
CV	Brovarone, et al., "Occhio e gravidanza", <i>Minerva Ginecol.</i> , Vol. 43, pp. 141-167 (1991)
CW	Browne, M.J. et al., "Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells", <i>Fibrinolysis</i> , Vol. 5, pp. 257-260 (1991)
CX	Bubl, et al., "Dysphagia in Dermatologic Disease", <i>Dysphagia</i> , Vol. 8, No. 2, pp. 85-90 (1993)
CY	Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration", <i>J. of Royal Society of Medicine</i> , Vol. 83, pp. 590, 591 (1990)

EXAMINER:	DATE CONSIDERED: 8/23/01
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/545,139
		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
Sheet 4 of 17		Attorney Docket Number	05213-0650 43170-219681

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


DA	Buelens, I., "Treatment of a Grade II Astrocytoma with Thalidomide (Phthalylglutamic Acid Imide) [Behandlung eines Astrocytoms II. Grades mit Thaliodmid (N-Phthalylglutaminsäureimid)], <i>Arzneim.-Forsch.</i> , Vol. 17, No. 5, pp. 646-648 (1967)
DB	Bullock, W.E., "The Clinical Significance of Erythema Nodosum", <i>Hosp. Pract.</i> , Vol. 21, No. 3, pp. 102E-2H, 102K-2L, 102Q-2R pas (1986)
DC	Burger, et al., "Epidermolysis Bullosa Acquisita, a Rare Late Complication of Allogeneic Bone Marrow Transplantation?", <i>Bone Marrow Transplant</i> , Vol. 9, No. 2, pp. 139-141 (1992)
DE	Burrows, N.P., "Thalidomide Modifies Disease", <i>Brit. Med. J.</i> , Vol. 307, No. 6909, pp. 939-940 (1993)
DF	Buckley, C. et al., "Pyoderma Gangrenosum with Severe Pharyngeal Ulceration", <i>J. of the Royal Soc. of Med.</i> , Vol. 83, pp. 590-591 (1990)
DG	Calnan, et al., "Actinic Prurigo (Hutchinson's Summer Prurigo)", <i>Clin. Exp. Dermatol.</i> , Vol. 2, No. 4, pp. 365-372 (1977)
DH	Cant, J.S., "Minor Ocular Abnormalities Associated With Thalidomide", <i>The Lancet</i> , p. 1134 (1966)
DI	Carmichael, et al., "Thalidomide: A Restricted Role", <i>Lancet</i> , Vol. 339, No. 8805, p. 1362 (1992)
DJ	Cashin, C.H. et al., "Angiogenesis and Chronic Inflammation", <i>Agents and Actions</i> , Vol. 34, No. 3/4, pp. 332-338 (1991)
DK	Casini, G. et al., "Preparazione Di Uno Degli Antipodi Ottici Della 2-Ftalimidoglutarimide", <i>Il Pharmaco. Ed. Sc.</i> , Vol XIX, Fasc. 6, pp. 563-565 (1964)
DL	Caswell, L.R. et al., "Nitrophthaloyl and aminophthaloyl derivatives of amino acids", <i>J. Chem. Eng. Data</i> , Vol. 13, No. 2, pp. 291-292 (1968) (Abstract only)
DM	Chapon, et al., "Neuropathies Caused by Thalidomide", <i>Rev. Neurol.</i> , Vol. 141, No. 11, pp. 719-728 (1985)
DN	Chaudhry, A. et al., "Effects of Prednisolone and Thalidomide on Induced Submandibular Gland tumors in Hamsters", <i>Canc. Res.</i> , Vol. 26, No. 9, Part 1, pp. 1884-1886 (1966)
DO	Chen, T. et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide after Oral Dosing in Healthy Male Volunteers", <i>The Am. Society for Pharma. and Experi. Therapeutics</i> , Vol. 17, No. 4, pp. 402-405 (1988)
DP	Chosidow, O. et al., "Scleroderma Chronic Graft-Versus-Host Disease: Analysis of Seven Cases", <i>J. Am. Acad. Dermatol.</i> , Vol. 26, No. 1, pp. 49-55 (1992)
DQ	Claydon, et al., "Gastrointestinal Emergencies in HIV Infection", <i>Balliere's Clin Gastroenterol.</i> , Vol. 5, No. 4, pp. 887-911 (1991)
DR	Clemmensen, et al., "Thalidomide Neurotoxicity", <i>Arch. Dermatol.</i> , Vol. 120, No. 3, pp. 338-341 (1984)
DS	Colville-Nash, P.R. et al., "Angiogenesis and rheumatoid arthritis: Pathogenic and Therapeutic Implications", <i>Ann. Rheum. Dis.</i> , Vol. 51, pp. 919-925 (1992)
DT	Congy, et al., "Plasma Zinc Levels in Elderly Patients Hospitalized in Long Stay Units. Correlations with Other Nutritional Markers, Immunological Tests and Survival", <i>Sem. Hop. Paris</i> , Vol. 59, No. 45, pp. 3105-3108 (1983)
DU	Costa, et al., "Aseptic Adenitis in a Patient with Pyoderma Gangrenosum", <i>Ann. Dermatol.</i> , Vol. 121, No. 8, pp. 550-552 (1994) (Abstract Only)
DV	Crain, E. et al., "The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis", <i>J. of Autoimmunity</i> , Vol. 2, pp. 197-202 (1989)
DW	Crawford, C.L., "Letter: Thalidomide in Erythema Nodosum Leprosum", <i>Lancet</i> , Vol. 2, No. 839, pp. 1201-1202 (1973)
DX	Crawford, C.L., "Treatment of Erythema Nodosum Leprosum with Thalidomide", <i>Lancet</i> , Vol. 2, No. 828, pp. 567-568 (1973)
DY	Crawford, C.L., "Use of Thalidomide in Leprosy [letter; comment]", <i>BMJ</i> , Vol. 302, No. 6729, pp. 1603-1604 (1991)

EXAMINER	DATE CONSIDERED
	8/23/01
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/545,139
		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
Sheet 5 of 17		Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	Crum, et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment", <i>Science</i> , Vol. 230, pp. 1375-1378 (1985)
EB	Current Bibliographies in Medicine, "Thalidomide: Potential Benefits and Risks", <i>National Inst. Health, National Library of Medicine</i> , pp. 1-72 (Jan. 1963—July 1997)
EC	Dark, et al., "Combretastin A-4, an Agent that Displays Potent and Selective Toxicity Toward Tumor Vasculature", <i>Cancer Research</i> , Vol. 37, pp. 1829-1834 (1997)
ED	David-Bajar, K.M., "Subacute Cutaneous Lupus Erythematosus", <i>J. Invest. Dermatol.</i> Vol. 100, No. 1, pp. 2s-8s (1993)
EE	D'Amato, R. J. et al., "Thalidomide is an Inhibitor of Angiogenesis", <i>Proc. Natl. Acad. Sci.</i> , Vol. 91, pp. 4082-4085 (1994)
EF	D'Amato, et al., "Angiogenesis Inhibition in Age-Related Macular Degeneration", <i>Ophthalmology</i> , Vol. 102, No. 9, pp. 1261-1262 (1995)
EG	D'Amato, et al., "Microscopic Analysis of Retinal Vessels Utilizing Fluorescein-Labeled High-Molecular-Weight Dextrans", <i>Invest. Ophthalmol. & Visual Science</i> , Vol. 33, No. 4, p. 1082 (1992)
EH	De, A.U. et al., "Possible Antineoplastic Agents I", <i>J. of Pharma. Sci.</i> , Vol. 64, No. 2, pp. 262-266 (1975)
EI	De, A.U. et al., "Possible Antineoplastic agents. III. Synthesis of 6-alkyl-2-[4-methoxyphthalimido] and 6-alkyl-3-[3'-4'-dimethoxyphenyl]glutarimides", <i>J. Indian Chem. Soc.</i> , Vol. 53, No. 11, pp. 1122-1125 (1976)
EJ	De, A.U. et al., "Possible Antineoplastic Agents: Part IV-Synthesis & Antineoplastic Potency of N-Substituted α -(4,5-Dimethoxyphthalimido)glutarimides and N-Substituted β -(4-Bromophenyl)glutarimides", <i>Indian J. of Chemistry</i> , Vol. 16B, pp. 510-512, (June 1978)
EK	De Cock, K., "Treatment of Ulcerative Colitis", <i>Brit. Med. J.</i> , Vol. 1, pp. 1356 (1979)
EL	DeKlerk, et al., "New Methods of Treatment for Renal Allografts Using the Baboon as a Primate Experimental Model", <i>J. Urol.</i> Vol. 102, No. 5, pp. 532-540 (1969)
EM	Dhodapkar, et al., "A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients with Multiple Myeloma", <i>UARK 98-003</i> , pp. 1-15 <i>no date</i>
EN	Dicken, C. H., "Malignant pyoderma", <i>J. of the Am. Acad. of Dermatol.</i> , Vol. 13, No. 6, pp. 1021-1025 (1985)
EO	DiPaolo, et al., "Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro", <i>Science</i> , Vol. 144, pp. 1583 (1964)
EP	DiPaolo, "Effect of Thalidomide on a Variety of Transplantable Tumors", <i>Cancer Chemo. Reports</i> , Vol. 29, pp. 99-102 (1963)
EQ	DiPaolo, "In Vitro Test Systems for Cancer Chemotherapy. II. Correlation of In Vitro Inhibition of Dehydrogenase and Growth with In Vivo Inhibition of Ehrlich Ascites Tumor", <i>P.S.E.B.M.</i> , Vol. 114, pp. 384-387 (1963)
ER	DiPaolo et al., "Teratogenesis-oncogenesis: A Study of Possible Relationships", <i>Arch. Path.</i> , Vol. 81, pp. 3-23 (1966)
ES	Dorveaux, et al., "Le Traitement Actuel du Lupus Erythemateux Chronique", <i>Le Concours Med.</i> Vol. 106, No. 31, pp. 2957-2961 (1984)
ET	Doutre, et al., "Pyoderma Gangrenosum and Hemopathies. A propos of 2 Cases", <i>Nouv Rev Fr Hematol</i> , Vol. 29, No. 4, pp. 251-254 (1987)
EU	Dunn, et al., "Bone Marrow Transplantation and Cataract Development", <i>Arch. Ophthalmol.</i> Vol. 111, No. 10, pp. 1367-1373 (1993)
EV	(Editorial) "Thalidomide in Dermatology and Leprosy", <i>Lancet</i> , Vol. 2, No. 8446, pp. 80-81 (1985)
EW	(Editorial) "Thalidomide Tested for Treatment of AIDS", <i>U.S. Pharm.</i> , Vol. 18, No. 8, p. 14 (1993)
EX	Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide", <i>Arzheim. Forsch/Drug Res.</i> , Vol. 40 (II), No. 10, pp. 1073-1075 (1990)
EY	Ehrlich, G.E. "Behcet's Disease: Current Concepts", <i>Comprehensive Therapy</i> , Vol. 15, No. 1, pp. 27-30 (1989)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AUG 03 2001
TECH CENTER 1600/2900

RECEIVED



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO		Complete if Known	
		Application Number	09/545,139
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
		Attorney Docket Number	05213-0650 43170-219681
Sheet	6 of 17		

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


FA	El-Naggar, A.M., et al., "Synthesis of Biologically Active 3,5-dinitrophthaloyl- and 3,5- diaminophthaloyl-amino acids and dipeptide derivatives", Indian J. Chem., Sect. B (1981) pp. 514-17, abstract only
FB	Elia, et al., "Giant Esophageal Ulcer Treated with Steroids in AIDS Patient(2)", <i>J. Acquired Immune Defic. Syndr.</i> , Vol. 5, No. 8, pp. 848-849 (1992)
FC	Eisenbud, L. et al., "Recurrent Aphthous Stomatitis of the Behcet's Type: Successful Treatment with Thalidomide", <i>Oral Surgery, Oral Medicine, Oral Pathology</i> , Vol. 64, No. 3, pp. 289-292 (1987)
FD	Eravelly, J. et al., "Thalidomide in Weber-Christian Disease", <i>The Lancet</i> , Vol. 1, No. 8005, p. 251 (1977)
FE	Eriksson, et al., "Drug Exposure and Flow Cytometry Analyses in a Thalidomide Treatment Schedule that Prolongs Rat Cardiac Graft Survival", <i>Transplant Proc.</i> , Vol. 24, No. 6, pp. 2560-2561 (1992)
FF	Eriksson, S. O. et al., "Synthesis and Alkaline Hydrolysis of Some N-substituted Phthalimides", <i>Acta Pharm. Suecica</i> , Vol. 10, pp. 63-74 (1973)
FG	Fabro, S. et al., "The Metabolism of Thalidomide: Some Biological Effects of Thalidomide and its Metabolites", <i>Brit. J. Pharmacol.</i> , Vol. 25, pp. 352-362 (1965)
FH	Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds", <i>Life Sci.</i> , Vol. 3, pp. 987-992 (1964)
FI	Fabro, S. M.D., "Biochemical Basis of Thalidomide Teratogenicity", <i>The Biochemical Basis of Chemical Teratogenesis</i> , Chapter 5, pp. 159-178 (1981)
FJ	Fajardo, et al., "Dual Role of Tumor Necrosis Factor- α in Angiogenesis", <i>Am. J. Pathol.</i> , Vol. 140, No. 3, pp. 539-544 (1992)
FK	Faure, et al., "PMN Leukocytes Chemotaxis: Inhibition by Thalidomide", <i>Pathol. Biol. (Paris)</i> , Vol. 29, No. 10, pp. 601-604 (1981)
FL	Faure, et al., "Inhibition of PMN Leukocytes Chemotaxis by Thalidomide", <i>Arch. Dermatol. Res.</i> , Vol. 269, No. 3, pp. 275-280 (1980)
FM	Fazal, N. et al., "Effect of Blocking TNF- α on Intracellular BCG (<i>Bacillus Calmette Guerin</i>) Growth in Human Monocyte-Derived Macrophages", <i>FEMS Microbiology Immunology</i> , Vol. 105, pp. 337-346 (1992)
FN	Fickentscher, K. et al., "Stereochemical Properties and Teratogenic Activity of Some tetrahydrophthalimides", <i>Mol. Pharmacol.</i> , Vol. 13, pp. 133-141 (1977)
FO	Field, E. O. et al., "Effect of Thalidomide on Splenomegaly (GVH Reaction) in the Chick Embryo. Treatment of Donor Cells Only", <i>Nature</i> , Vol. 211, No. 5055, pp. 1309-1310 (1966)
FP	Flohe, L. et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis", <i>Arzneimittelforschung (Germany West)</i> , Vol. 31, No. 2, pp. 315-320 (1981)
FQ	Folkman, J. et al., "Angiogenesis", <i>J. Biol. Chem.</i> , Vol. 267, No. 16, pp. 10931-10934 (1992)
FR	Folkman, J. et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone", <i>Science</i> , Vol. 221, pp. 719-725 (1983)
FS	Folkman, J. et al., "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia", <i>Nature</i> , Vol. 339, pp. 58-61 (1989)
FT	Folkman, J. et al., "Tumor Behavior in Isolated Perfused Organs: In Vitro Growth and Metastases of Biopsy material in Rabbit Thyroid and Canine Intestinal Segment", <i>Annals of Surgery</i> , pp. 491-502 (1966)
FU	Folkman, J., "Tumor Angiogenesis: Therapeutic Implications", <i>The New England J. of Med.</i> , Vol. 285, No. 21, pp. 1182-1186, (1971)
FV	Folkman, J., "Angiogenesis and Its Inhibitors", <i>Important Advances in Oncology</i> , J.B. Lippincott H. Company, pp. 42-62 (1985)
FW	Folkman, J., "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease", <i>Nature Medicine</i> , Vol. 1, No. 1, pp. 27-30 (1995)
FX	Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?", <i>J. Natl' Cancer Inst.</i> , Vol. 82, No. 1, (1990)
FY	Francois, J., "Embryological Pigment Epithelial Dystrophies", <i>Ophthalmologica</i> , Vol. 172, pp. 417-433 (1976)
FZ	Fuller, et al., "Thalidomide, Peripheral Neuropathy and AIDS", <i>Int. J. STD AIDS</i> , Vol. 2, No. 5, pp. 369-370 (1991)

EXAMINER

DATE CONSIDERED

8/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/545,139
		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
Sheet 7 of 17	of	Attorney Docket Number	05213-0650 43170-219681


U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

GA	Furner, B.B., "Treatment of Subacute Cutaneous Lupus Erythematosus", <i>Int. J. Dermatol.</i> , Vol. 29, No. 8, pp. 542-547 (1990)
GB	Gad, et al., "Thalidomide Induces Imbalances in T-Lymphocyte Sub-Populations in the Circulating Blood of Healthy Males", <i>Lepr. Rev.</i> , Vol. 56, No. 1, pp. 35-39 (1985)
GC	Gaetani, M., "Studi Sull'Attività Antitumorale Della Thalidomide", <i>Giornale Italiano di Chemioterapia</i> , pp. 83-86 <i>no date</i>
GD	Gehanno, et al., "Mouth and Pharyngeal Hyperalgesic Syndromes in AIDS", <i>Ann. Otolaryngol. Chir. Cervicofac.</i> , Vol. 107, No. 5, pp. 311-313 (1990)
GE	Genov, et al., "Treatment of Aphthosis with Thalidomide and with Colchicine", <i>Dermatologica</i> , Vol. 168, No. 4, pp. 182-188 (1984)
GF	Geoghiou, et al., "HIV-Associated Oesophageal Ulcers Treated with Thalidomide", <i>Med. J. of Australia</i> , Vol. 152, pp. 382-383 (1990)
GG	Gershbein, "Effect of Transplanted Tumor and Various Agents on Liver Regeneration During Pregnancy", <i>P.S.E.B.M.</i> , Vol. 126, pp. 88-92 (1967)
GH	Gershbein, L. L., "The Thalidomide Analog, EM 12, Enhances 1,2-dimethylhydrazine-induction of Rat Colon Adenocarcinomas", <i>Canc. Ltrs.</i> , Vol. 60, pp. 129-133 (1991)
GI	Gershbein, L. L., "Effect of Various Agents on Liver Regeneration and Walker Tumor-Growth in Partially Hepatectomized Rats", <i>Canc. Res.</i> , Vol. 26, No. 9, pp. 1905-1908 (1966)
GJ	Ghigliotti, G. et al., "Thalidomide: Treatment of Choice for Aphthous Ulcers in Patients Seropositive for Human Immunodeficiency Virus", <i>J. of the Am. Acad. of Dermatol.</i> , Vol. 28, No. 2, Part I, pp. 271-272 (1993)
GK	Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovascularization", <i>Journal of Experimental Medicine</i> , Vol. 136, pp. 261-276 (1972)
GL	Gimbrone, M. A. et al., "Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea", <i>J. Nat. Canc. Instit.</i> , Vol. 52, No. 2, pp. 413-419 (1974)
GM	Goihman-Yahr, Mauricio et al., "Significance of Neutrophil Activation in Reactional Lepromatous Leprosy: Effects of Thalidomide in vivo and in vitro. Activation in Adjuvant Disease", <i>Int. Archs. Allergy Appl. Immun.</i> , Vol. 57, pp. 317-332 (1978)
GN	Goihman-Yahr, M., et al., "Autoimmune Diseases and Thalidomide II. Adjuvant Disease, Experimental Allergic Encephalomyelitis and Experimental Allergic Neuritis of the Rat", <i>Int. J. Leprosy</i> , Vol. 42, No. 3, pp. 266-275 (1974)
GO	Gorin, I., et al., "Thalidomide May Cure AIDS Ulcers", <i>Nurs. Times</i> , Vol. 86, No. 24, p. 10 (1990)
GP	Gorin, I., et al., "Thalidomide in Hyperalgesic Pharyngeal Ulceration of AIDS", <i>Lancet</i> , Vol. 335, p. 1343 (1990)
GQ	Goulden, V., et al., "Linear Prurigo Simulating Dermatitis Artefacta in Dominant Dystrophic epidermolysis Bullosa", <i>Br. J. Dermatol.</i> , Vol. 129, No. 4, pp. 443-446 (1993)
GR	Grabstald, H. et al., "Clinical Experiences with Thalidomide in Patients with Cancer", <i>Clinical Pharmacol. and Therapeutics</i> , Vol. 6, pp. 298-302 (1965)
GS	Grant, D.S. et al., "Scatter Factor Induces Blood Vessel Formation in vivo", <i>Proc. Natl. Acad. Sci.</i> , Vol. 90, pp. 1937-1941 (1993)
GT	Grinspan, et al., "Treatment of Aphthae with Thalidomide", <i>J. Am. Acad. Dermatol.</i> , Vol. 20, No. 6, pp. 1060-1063 (1989)
GU	Grinspan, D., "Significant Response of Oral Aphthosis to Thalidomide Treatment", <i>Am. Acad. of Dermatol.</i> , Vol. 12, No. 1, Part 1, pp. 85-90 (1985)

EXAMINER	DATE CONSIDERED 8/23/01
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
AUG 03 2001
TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Substitute for Form 1449/A/PTO		Application Number	09/545,139
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
		Attorney Docket Number	05213-0650 43170-219681
Sheet	8 of 17		

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

HA	Grosshans, E., et al., "Thalidomide Therapy for Inflammatory Dermatoses", <i>Int. J. Dermatol.</i> , Vol. 23, No. 9, pp. 598-602 (1984)
HB	Guidetti, E., et al., "Ricerche Sull'azione Immunodepressiva Della Talidomide e del Prednisolone in Ratti Portatori Di Neoplasie Sperimentalmente Indotte", <i>Cancro</i> , Vol. 22, pp. 503-512 (1969)
HC	Günzler, V., "Thalidomide in Human Immunodeficiency Virus (HIV) Patients. A Review of Safety Considerations", <i>Drug Saf.</i> , Vol. 7, No. 2, pp. 116-134 (1992)
HD	Günzler, V., "Thalidomide—A Therapy for the Immunological Consequences of HIV Infection?", <i>Medical Hypotheses</i> , Vol. 30, No. 2, pp. 105-109 (1989)
HE	Gutiérrez-Rodríguez, O. et al., "Treatment of Refractory Rheumatoid Arthritis—The Thalidomide Experience", <i>The J. of Rheumatology</i> , Vol. 16, No. 2, pp. 158-163 (1989)
HF	Gutiérrez-Rodríguez, O. et al., "Thalidomide A Promising New Treatment for Rheumatoid Arthritis", <i>Arthritis and Rheumatism</i> , Vol. 27, No. 10, pp. 1118-1121 (1984)
HG	Haffner, M.E. M.D., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", <i>Food and Drug Law Journal</i> , Vol. 48, pp. 205-211 (1992)
HH	Hamza, M. M.D., "Behcet's Disease, Palmoplantar Pustulosis and HLA-B27 Treatment with Thalidomide", <i>Clinical and Experimental Rheumatology</i> , Vol. 8, No. 4, p. 427 (1990)
HI	Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", <i>Clinical Rheumatol.</i> , Vol. 5, No. 3, pp. 365-371 (1986)
HJ	Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Pediatric Dermatol.</i> , Vol. 10, No. 3, pp. 256-258, (1993)
HK	Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", <i>Brit. J. of Dermatol.</i> , Vol. 127, Supp. 40, pp. 67-68 (1992)
HL	Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Humanimmunodeficiency Virus(1)", <i>Arch. Intern. Med.</i> , Vol. 152, No. 9, p. 1924 (1992)
HM	Harris, A., "Antiangiogenesis for Cancer Therapy", <i>Lancet</i> , Vol. 349 (Suppl. II), pp. 13-15 (1997)
HN	Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", <i>Arch. Dermatol.</i> , Vol. 19, No. 10, pp. 812-815 (1983)
HO	Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", <i>Acta. Derm. Venereol.</i> , Vol. 62, No. 4, pp. 321-324 (1982)
HP	Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Selected Laboratory Abnormalities in Erythema Nodosum Leprosum", <i>Clin. Pharmacol. Ther.</i> , Vol. 11, No. 4, pp. 481-487 (1970)
HQ	Hatfill, S.J. et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", <i>Leukemia Res.</i> , Vol. 15, No. 2/3, pp. 129-136 (1991)
HR	Hayashi, S. et al., "A Synthetic Peptide for α Chemokines Inhibits the Growth of Melonoma Cell Lines", <i>J. Clin. Invest.</i> , Vol. 99, No. 11, pp. 2581-2587 (1997)
HS	Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", <i>J. R. Soc. Med.</i> , Vol. 85, No. 6, pp. 313-314 (1992)
HT	Hellman, K. et al., "Prolongation of Skin Homograft Survival by Thalidomide", <i>Brit. Med. J.</i> , Vol. 2, pp. 687-689 (1965)
HU	Helm, F.-Ch. et al., "Comparative Teratological Investigation of Compounds Structurally and Pharmacologically Related to Thalidomide", <i>Arzneim.-Forsch./Drug Res.</i> , Vol. 31 (I), No. 6, pp. 941-949 (1981)


EXAMINER

DATE CONSIDERED

8/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
AUG 03 2001
TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 17

Complete if Known

Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

IA	Hendler, S. S. et al., "Thalidomide for Autoimmune Disease", <i>Medical Hypotheses</i> , Vol. 10, pp. 437-443 (1983)
IB	Hendler, S.S., "Immune Modulators Thalidomide", <i>The Oxygen Breakthrough</i>, pp. 217-219 no date
IC	Heney, D. et al., "Thalidomide Treatment for Chronic Graft-Versus-Host Disease", <i>Brit. J. of Haematol.</i> Vol. 78, pp. 23-27 (1991)
ID	Heney, D., et al., "Thalidomide in the Treatment of Graft-versus-Host Disease", <i>Biomed. Pharmacother.</i> , Vol. 44, No. 4, pp. 199-204 (1990)
IE	Heney, D., et al., "Thalidomide for Chronic Graft-versus-Host Disease in Children", <i>Lancet</i> , Vol. 2, No. 8623, p. 1317 (1988)
IF	Hojyo, et al., "Actinic Prurigo (9)", <i>Int. J. Dermatol.</i> , Vol. 31, No. 5, pp. 372-373 (1992)
IG	Holm, et al., "Chronic Cutaneous Lupus Erythematosus Treated with Thalidomide", <i>Arch. Dermatol.</i> , Vol. 129, No. 12, pp. 1548-1550 (1993)
IH	Hori, A. et al., "Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor", <i>Canc. Res.</i> , Vol. 51, pp. 6180-6184 (1991)
II	Hu, D.E., "Inhibition of Angiogenesis in Rats by IL-1 Receptor Antagonist and Selected Cytokine Antibodies", <i>Inflammation</i> , Vol. 18, pp. 45-58 (1994)
IJ	Hu, J. et al., "A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells", <i>The FASEB Journal</i> , Vol. 11, pp. 498-504 (1997)
IK	Ingber, D. et al., "Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumor Growth", <i>Ltrs. to Nat.</i> , Vol. 348, pp. 555-557 (1990)
IL	Ingber, D., "Drug News and Trial Developments", <i>AIDS Patient Care</i> , Vol. 6, No. 6, p. 288 (1992)
IM	Jacobson, J. et al., "Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection", <i>The New England Journal of Medicine</i> , Vol. 336, No. 21, pp. 1487-1493 (1997)
IN	Jacobson, et al., "The Diagnosis and Treatment of Leprosy", <i>South Med. J.</i> , Vol. 69, No. 8, pp. 979-985 (1976)
IO	Jager, et al., "Clinical Observations in the Treatment of Leprosy Reaction with Cyclic Imides", <i>Int. J. Lepr. Other Mycobact Dis.</i> , Vol. 39, No. 2, p. 589 (1971)
IP	Jeltsch, M. et al., "Hypertrophy of Lymphatic Vessels in VEGF-C Transgenic Mice", <i>Science</i> , Vol. 276, pp. 1423-1426 (1997)
IQ	Jenkins, et al., "Thalidomide, Orogenital Ulcers, and Risk of Teratogenicity", <i>The Lancet</i> , Vol. 1, No. 8417-18, p. 511 (1985)
IR	Jenkins, et al., "Thalidomide in Severe Orogenital Ulceration", <i>The Lancet</i> , Vol. 2, No. 8417-18, pp. 1424-1426 (1984)
IS	Jennings, et al., "Effect of Actinomycin D on the Production of Acute Phase Protein in the Rabbit", <i>Experientia</i> , Vol. 25, pp. 305-306 (1969)
IT	Jew, et al., "Thalidomide in Erythema Nodosum Leprosum", <i>DICP</i> , Vol. 24, No. 5, pp. 482-483 (1990)
IU	Johnke, et al., "Thalidomide Treatment of Prurigo Nodularis", <i>Ugeskr Laeger</i> , Vol. 155, No. 38, pp. 3028-3030 (1993) (Abstract Only)
IV	Jönsson, N., "Chemical Structure and Teratogenic Properties IV. An Outline of a Chemical Hypothesis for the Teratogenic Action of Thalidomide", <i>Acta Pharm. Succica</i> , Vol. 9, pp. 543-562 (1972)
IW	Jönsson, N., "Chemical Structure and Teratogenic Properties I. Synthesis and Teratogenic Activity in Rabbits of some Derivatives of Phthalidimide, Isoindoline-1-one, 1,2-Benzisothiazoline-3-one-1, 1-Dioxide and 4(3II)-Quinazolinone", <i>Acta Pharm Succica</i> , Vol. 9, pp. 431-436 (1972)
IX	Jönsson, N., "Chemical Structure and Teratogenic Properties III. A Review of Available Data on Structure-Activity Relationships and Mechanism of Action of Thalidomide Analogues", <i>Acta Pharm. Succica</i> , Vol. 9, pp. 521-542 (1972)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/545,139
	Filing Date	April 7, 2000
	First Named Inventor	D'Amato et al.
	Group Art Unit	1614
	Examiner Name	J. Goldberg
	Attorney Docket Number	05213-0650 43170-219681

Sheet 10 of 17

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

JA	Jorizzo, et al., "Thalidomide Effects in Behcet's Syndrome and Pustular Vasculitis", <i>Arch. Intern. Med.</i> , Vol. 146, No. 5, pp. 878-881 (1986)
JB	Juret, et al., "Absence d'effet Carcino-Frénateur du Talidomide vis-à-vis de deux Tumeurs Greffées", <i>Société de Biologie</i> , Vol. 23, pp. 246-249 (1963)
JC	Kaitin, K.I., "Graft-versus-Host Disease", <i>N. Engl. J. Med.</i> , Vol. 325, No. 5, pp. 357-358 (1991)
JD	Kaplan, G. et al., "TNF α regulation of HIV1: Biology and Therapy", <i>Res. in Immunology</i> , Vol. 145, No. 8-9, pp. 685-690 (1994)
JE	Katsuta, et al., "Carcinogenesis in Tissue Culture. 3. Effects of the Second Treatments on DAB-Induced Proliferating Liver Cells of Normal Rats in Culture", <i>Jpn. J. Exp. Med.</i> , Vol. 35, No. 4, pp. 231-248 (1965)
JF	Keenan, R.J. et al., "Immunosuppressive Properties of Thalidomide", <i>Transplantation</i> , Vol. 52, No. 5, pp. 908-910 (1991)
JG	Kenyon, et al., "The Discovery of New Inhibitors of Angiogenesis Using an Improved Mouse Corneal Neovascularization Model", No. 459-367, p. S94 (Abstract only) <i>no date</i>
JH	Kim, K. J. et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth <i>in vivo</i> ", <i>Ltrs. to Nat.</i> , Vol. 362, pp. 841-844 (1993)
JI	Kitamoto, Y. et al., "Vascular Endothelial Growth Factor is an Essential Molecule for Mouse Kidney Development: Glomerulogenesis and Nephrogenesis", <i>J. Clin. Invest.</i> , Vol. 99, No. 10, pp. 2351-2357 (1997)
JJ	Klug, S. et al., "Embryotoxic Effects of Thalidomide Derivatives in the Non-Human Primate Callithrix Jacchus", <i>Arch. Toxicol.</i> Vol. 68, pp. 203-205 (1994)
JK	Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", <i>Br. J. Canc.</i> , Vol. 35, pp. 347-356 (1977)
JL	Knop, et al., "Thalidomide in the Treatment of Sixty Cases of Chronic Discoid Lupus Erythematosus", <i>Br. J. Dermatol.</i> , Vol. 108, No. 4, pp. 461-466 (1983)
JM	Koch, H.P. et al., "4 Thalidomide and Congeners as Anti-inflammatory Agents", <i>Progress in Medicinal Chemistry</i> , Vol. 22, pp. 166-242 (1985)
JN	Korn, et al., "The Second International Workshop on Scleroderma Research", <i>Matrix</i> , Vol. 13, No. 5, pp. 427-429 (1993)
JO	Kroger, et al., "Synergistic Effects of Thalidomide and Poly (ADP-ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice", <i>Inflammation</i> , Vol. 20, No. 2, pp. 203-215 (1996)
JP	Kundu, et al., "Prurigo Nodularis in an HIV Positive Man (2)", <i>Genitourinary Medicine</i> , Vol. 71, No. 2, pp. 129-130 (1995)
JQ	Kürkcüoglu, N. et al., "Thalidomide in the treatment of Recurrent Necrotic Mucocutaneous Aphthae", <i>Brit. J. of Dermatol.</i> , Vol. 112, No. 5, pp. 632 (1985)
JR	Lane, et al., "Treatment of Actinic Prurigo with Intermittent Short-Course Topical 0.05% Clobetasol 17-Propionate. A Preliminary Report", <i>Arch. Dermatol.</i> , Vol. 126, No. 9, pp. 1211-1213 (1990)
JS	Languillon, J., "The Effects of Thalidomide on Leprosy Reaction", <i>Int. J. Lepr. Other Mycobact. Dis.</i> , Vol. 39, No. 2, pp. 590-592 (1971)
JT	Larsson, H., "Treatment of Severe Colitis in Behcet's Syndrome with Thalidomide (CG-217)", <i>J. of Intern. Med.</i> , Vol. 228, pp. 405-407 (1990)
JU	Ledo, E., "Photodermatosis. Part I: Photobiology, Photoimmunology, and Idiopathic photodermatoses", <i>Int. J. Dermatol.</i> , Vol. 32, No. 6, pp. 387-396 (1993)
JV	Lehner, T., et al., "Thalidomide, Orogenital Ulcers, and the Risk of Teratogenesis", <i>The Lancet</i> , Vol. 8423, pp. 288-289 (1985)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/545,139
		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
Sheet 11 of 17		Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

KA	Lenicque, "Action of Thalidomide on the Induction of Tentacles in Regenerating Hydra Littoralis", <i>Acta. Zool.</i> , pp. 127-139 (1967)
KB	Levy, et al., "Treatment of Erythema Nodosum Leprosum with Thalidomide", <i>The Lancet</i> , Vol. 2, No. 824, pp. 324-325 (1973)
KC	Lien, W. M. et al., "The Blood Supply of Experimental Liver Metastases. II. A microcirculatory Study of the Normal and Tumor Vessels of the Liver with the Use of Perfused Silicone Rubber", <i>Surgery</i> , Vol. 68, No. 2, pp. 334-340 (1970)
KD	Lo, et al., "Treatment of Discoid Lupus Erythematosus", <i>Int. J. Dermatol.</i> , Vol. 28, No. 8, pp. 497-507 (1989)
KE	Londono, F., "Thalidomide in the Treatment of Actinic Prurigo", <i>Int. J. Dermatol.</i> , Vol. 12, No. 5, pp. 326-328 (1973)
KF	Lovell, et al., "Thalidomide in Actinic Prurigo", <i>Br. J. Dermatol.</i> , Vol. 108, No. 4, pp. 467-471 (1983)
KG	Lopez, J. et al., "Thalidomide as Therapy for Intestinal Chronic GVHD", <i>Bone Marrow Transplantation</i> , Vol. 11, No. 3, pp. 251-252 (1993)
KH	Louzir, B. et al., "Erythroleucemie chez un patient ayant une maladie de Behcet et traite au long cours par thalidomide", <i>Annales de Medecine Interne</i> , Vol. 143, pp. 479-480 (1992)
	Lueprasitsakul, W. et al., "Effect of Thalidomide on the Incidence of Iodine-Induced and Spontaneous KI Lymphocytic Thyroiditis and Spontaneous Diabetes Mellitus in the BB/Wor Rat", <i>Acta Endocrinologica</i> , Vol. 123, pp. 79-83 (1990)
KJ	Lüers, H., "Failure of Mutagenic Action of Thalidomide in Drosophila", <i>The Lancet</i> , Vol. II, No. 7258, p. 1332 (1962)
KK	Magana-Garcia, M., "Antimalarials for Children", <i>J. Am. Acad. Dermatol.</i> , Vol. 30, No. 3, p. 510 (1994)
KL	Maione, T. E. et al., "Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides", <i>Science</i> , Vol. 2, pp. 77-78 (1990)
KM	Makonkawkeyoon, S. et al., "Thalidomide Inhibits the Replication of Human Immunodeficiency virus type 1", <i>Proc. Natl. Acad. Sci.</i> , Vol. 90, pp. 5974-5978 (1993)
KN	Marin-Padilla, M. et al. "Thalidomide Induced alterations in the Blastocyst and Placenta of the Armadillo, Dasyus Novemcinctus Mexicanus, Including a Choriocarcinoma", <i>The Am. J. of Pathol.</i> , Vol. 43, No. 6, pp. 999-1016 (1963)
KO	Mascaro, et al., "Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis", <i>Arch. Dermt.</i> , Vol. 115, pp. 636-637 (1979)
KP	Matsubara, et al., "Inhibition of Human Endothelial Cell Proliferation by Gold Compounds", <i>J. Clin. Invest.</i> , Vol. 79, pp. 1440-1446 (1987)
KQ	Matsuyama, T. et al., "Cytokines and HIV Infection: is AIDS a Tumor Necrosis Factor Disease?", <i>AIDS</i> , Vol. 5, No. 12, pp. 1405-1417 (1991)
KR	Mauad, "Melhoras Clínicas Obtidas em Doentes Cancerosos Avançados com Tratamento Pela Talidomida Associada a Hormônios", <i>Anais Paulistas Medicina e Cirurgia</i> , pp. 15-39 (1963)
KS	Maurice, et al., "The Effect of Thalidomide on Arachidonic Acid Metabolism in Human Polymorphonuclear Leukocytes and Platelets", <i>Br. J. Dermatol.</i> , Vol. 115, No. 6, pp. 677-680 (1986)
KT	McCarthy, et al., "Thalidomide for the Therapy of Graft-versus-Host Disease Following Allogeneic Bone Marrow Transplantation", <i>Biomed. Pharmacother.</i> , Vol. 43, No. 9, pp. 693-697 (1989)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 17

Complete if Known

Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

- | | |
|----|---|
| LA | McKenna, et al., "Linear IgA Disease, Oral Ulceration and Crohn's Disease", <i>Br. J. Dermatol.</i> , Vol. 127, pp. 67-68 (1992) |
| LB | Meza, D. et al., "Managing the Gastrointestinal Complications of AIDS", <i>Drug Therapy</i> , Vol. 23, No. 11, pp. 74-83 (1993) |
| LC | Miller, et al., "Zusammentreffen Einer Thalidomid-Induzierten Fehlbildung mit Einem Malignen Lymphom Hohen Malignitätsgrades", <i>Monatsschr. Kinderheilkd.</i> , Vol. 128, pp. 27-29 (1980) |
| LD | Miller, et al., "Treatment of Chronic Erythema Nodosum Leprosum with Cyclosporine A Produces Clinical and Immunohistologic Remission", <i>Int. J. Lepr. Other Mycobact. Dis.</i> , Vol. 55, No. 3, pp. 441-449 (1987) |
| LE | Misery, L. et al., "Remission of Langerhans Cell Histiocytosis with Thalidomide Treatment", <i>Clinical and Experimental Dermatol.</i> , Vol. 18, No. 5, p. 487 (1993) |
| LF | Miura, M. et al., "Potentiating Effect of Thalidomide on Methylcholanthrene Oncogenesis in Mice", <i>Experientia</i> , Vol. 26, Fasc. 3, pp. 305-306 (1970) |
| LG | Miyachi, Y., "A Possible Mechanism of Action of Thalidomide on Rheumatoid Arthritis", <i>Arthritis and Rheuma</i> , Vol. 28, No. 7, p. 836 (1985) |
| LH | Miyachi, et al., "Effects of Thalidomide on the Generation of Oxygen Intermediates by Zymosan-Stimulated Normal Polymorphonuclear Leukocytes", <i>Arch. Dermatol. Res.</i> , Vol. 274, Nos. 3-4, pp. 363-367 (1982) |
| LI | Mohri, et al., "Negative Effect of Thalidomide and Relative Substances on the Growth of HeLa Cells", <i>Chem. Pharm. Bull.</i> , Vol. 16, pp. 2289-2292 (1968) |
| LJ | Moncada, et al., "Thalidomide - Effect on T Cell Subsets as a Possible Mechanism of Action", <i>Int. J. Lepr. Other Mycobact. Dis.</i> , Vol. 53, No. 2, pp. 201-205 (1985) |
| LK | Montrucchio, et al., "Tumor Necrosis Factor α -Induced Angiogenesis Depends on In Situ Platelet-Activating Factor Biosynthesis", <i>J. Exp. Med.</i> , Vol. 180, pp. 377-382 (1994) |
| LL | Moulin, et al., "Treatment of Jessner-Kanof Disease with Thalidomide", <i>Ann. Dermatol. Venereol.</i> , Vol. 10, No. 8, pp. 611-614 (1983) |
| LM | Mshana, et al., "Thymus-Dependent Lymphocytes in Leprosy. II. Effect of Chemotherapy on T-Lymphocyte Subpopulations", <i>J. Clin. Immunol.</i> , Vol. 2, No. 2, pp. 69-74 (1982) |
| LN | Mückter, et al., "Thalidomide and Tumor", <i>Antimicrobial Agents and Chemotherapy</i> , pp. 531-538 (1965) |
| LO | Mummery, C.L. et al., "Screening for Cytotoxicity in Neuroblastoma Cells-I. Dependence of Growth Inhibition on the Presence of Serum", <i>Toxicology Letters</i> , Vol. 18, pp. 201-209 (1983) |
| LP | Munro, et al., "Pyoderma Gangrenosum Associated with Behcet's Syndrome-Response to Thalidomide", <i>Clin. Exp. Dermatol.</i> , Vol. 13, No. 6, pp. 408-410 (1988) |
| LQ | Muthukaruppan, Vr. et al., "Angiogenesis in the Mouse Cornea", <i>Science</i> , Vol. 205, No. 28, pp. 1416-1418 (1979) |
| LR | Naafs, B. et al., "Thalidomide Therapy An Open Trial", <i>Intl. J. of Dermatol.</i> , Vol. 24, No. 2, pp. 131-134 (1985) |
| LS | Naafs, B., "Bangkok Workshop on Leprosy Research. Treatment of Reactions and Nerve Damage. <i>Int. J. Lepr. Other Mycobact. Dis.</i> , Vol. 64, No. 4, Suppl. S21-28 (1996) |
| LT | Neubert, "Teratogenicity: Any Relationship to Carcinogenicity?", <i>Institute for Toxicology and Embryopharmacology, Free University of Berlin, Berlin, Federal Rep. Of Germany</i> , pp. 169-178 <i>no date</i> |
| LU | Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", <i>J. of the Natl. Canc. Inst.</i> , Vol. 85, No. 3, pp. 241-242 (1993) |
| LV | Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Patients with a Wide Spectrum of Cancers", <i>J. of the Natl. Canc. Inst.</i> , Vol. 86, No. 5, pp. 356-361 (1994) (Abstract only) |
| LW | Nicolas, J., et al., "Interferon Alfa Therapy in Severe Unresponsive Subacute Cutaneous Lupus Erythematosus", <i>New Engl. J. Med.</i> , Vol. 321, No. 22, pp. 1550-1551 (1989) |

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 17

Complete if Known

Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


MA	Nicolau, et al., "Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with AIDS", <i>DICP</i> , Vol. 24, No. 11, pp. 1054-1056 (1990)
MB	Nielsen, et al., "Thalidomide Enhances Superoxide Anion Release from Human Polymorphonuclear and Leukocytes", <i>Acta. Pathol. Microbiol. Immunol. Scand. [C]</i> , Vol. 94, No. 6, pp. 233-237 (1986)
MC	Obeso, J. et al., "Methods in Laboratory Investigation A Hemangioendothelioma-Derived Cell Line: Its Use as a Model for the Study of Endothelial Cell Biology", <i>Laboratory Investigation</i> , Vol. 63, No. 2, pp. 259-269 (1990)
MD	Oikawa, T. et al., "Eponemycin, A Novel Antibiotic is a Highly Powerful Angiogenesis Inhibitor", <i>Biochem. and Biophys. Res. Comm.</i> , Vol. 181, No. 3, pp. 1070-1077 (1991)
ME	Olson, et al., "Thalidomide (N-phthaloylglutamimide) in the Treatment of Advanced Cancer", <i>Clin. Pharmacol. Therap.</i> , Vol. 6, No. 3, pp. 292-297 (1965)
MF	Orzalesi, M., "Il Danno Iatrogeno in Neonatologica", <i>Ped. Med. Chir.</i> , Vol. 14, pp. 105-112 (1992)
MG	Ostraat, et al., "Thalidomide Prolongs Graft Survival in Rat Cardiac Transplants", <i>Transplant Proc.</i> , Vol. 24, No. 6, pp. 2624-2625 (1992)
MH	Otsuka, et al., "A New Potent Angiogenesis Inhibitor, FR-118487", <i>J. of Microbiol. and Biotechnol.</i> , Vol. 13, No. 3, pp. 163-168 (1991)
MI	Paller, et al., "Proceedings of the Concurrent Sessions", <i>Pediatr. Dermatol.</i> , Vol. 9, No. 4, pp. 397-406 (1992)
MJ	Passaniti, A. et al., "Methods in Laboratory Investigation A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", <i>Laboratory Investigation</i> , Vol. 67, No. 4, pp. 519-528 (1992)
MK	Patey, O. et al., "Thalidomide et colite ulcereuse dans la maladie de Behcet", <i>Gastroenterol. Clin. Biol.</i> , Vol. 13, No. 104-110 (1989)
ML	Pearson, et al., "Treatment of Moderately Severe Erythema Nodosum Leprosum with Thalidomide - A Double-Blind Controlled Trial", <i>Lepr. Rev.</i> , Vol. 40, No. 2, pp. 111-116 (1969)
MM	Peyron, et al., "The Pharmacological Basis for the Treatment of Photodermatoses", <i>Biochimie</i> , Vol. 68, No. 6, pp. 899-904
MN	Pfordte, "Über die Beeinflussung des Serumproperdinsystems Durch Verschiedene Arzneimittel", <i>Pharmazie</i> , Vol. 26, pp. 301-302 (1971)
MO	Phillips, et al., "Tumor Necrosis Factor Alpha (rhTNF) Fails to Stimulate Angiogenesis in the Rabbit Cornea", <i>Anatomical Rec.</i> , Vol. 245, pp. 53-56 (1996)
MP	Powell, R.J. et al., "Investigation and Treatment of Orogenital Ulceration; studies on a Possible Mode of Action of Thalidomide", <i>Brit. J. of Dermatol.</i> , Vol. 113, Supp. 28, pp. 141-144 (1985)
MQ	Prigent, F. et al., "Sarcoidose cutanee Traitement par la Thalidomide", <i>La Presse Medicale</i> , Vol. 12, No. 47, p. 3007 (1983)
MR	Proenca, N.G., "Thalidomide: An Eclectic Medication in Dermatology", <i>Rev. Paul. Med.</i> , Vol. 107, No. 1, pp. 41-46. (Abstract Only)
MS	Radeff, et al., "Recurrent Aphthous Ulcer in Patient Infected with Human Immunodeficiency Virus: Successful Treatment with Thalidomide", <i>J. Am. Acad. Dermatol.</i> , Vol. 23, No. 3, Pt. 1, pp. 523-525 (1990)
MT	Rainsford, K.D., "Disease-Modifying Antirheumatic and Immunoregulatory Agents", <i>Bailliere's Clinical Rheumatology</i> , Vol. 4, No. 3, pp. 405-432 (1990)
MU	Rajan, et al., "A Clinical Study of Thalidomide Comparing Pre-Treatment and Post-Treatment Reactional Episodes and Corticosteroid Requirements", <i>Lepr. India</i> , Vol. 55, No. 1, 111-116 (1983)
MV	Randall, T., "Investigational New Drug (US) 'Orphan' Trials now Use Thalidomide from two Sources", <i>JAMA</i> , Vol. 263, No. 11, p. 1474 (1990)
	Randall, T., "Thalidomide's Back in the News, but in more Favorable Circumstances", <i>JAMA</i> , Vol. 263, No. 11, pp. 1467-1468 (1990)
MW	Revuz, J., "Actualite Du Thalidomide", <i>Ann. Dermatol. Venereol.</i> , Vol. 117, pp. 313-321 (1990)
EXAMINER	DATE CONSIDERED 8/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/08A (08-00)

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 17

Complete if Known

Application Number	09/545,139
Filing Date	April 7, 2000
First Named Inventor	D'Amato et al.
Group Art Unit	1614
Examiner Name	J. Goldberg
Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

NA	Revuz, J. et al., "Crossover Study of Thalidomide vs. Placebo in Severe Recurrent Aphthous Stomatitis", <i>Arch. Dermatol.</i> , Vol. 126, pp. 923-927 (1990)
NB	Rhoton, A. J., "Role for Thalidomide in Primary Biliary Cirrhosis Treatment?", <i>Gastroenterology</i> , Vol. 105, No. 3, p. 956 (1993)
NC	Robbins, K. C., "The Plasminogen-Plasmin Enzyme System", <i>Fibrinolysis</i> , pp. 340-357 (??) no date
ND	Roe, F.J.C., "Pathology Thalidomide and Neoplasia", <i>Nature</i> , Vol. 200, pp. 1016-1017 (1963)
NE	Roe, et al., "Tumour-Incidence in Progeny of Thalidomide-Treated Mice", <i>British J. Cancer</i> , pp. 331-333, (1965)
NF	Ruggenini, et al., "Talidomide e Tumori Sperimentali", <i>Cancro</i> , Vol. 20, pp. 39-55 (1967)
NG	Rustin, et al., "Pyoderma Gangrenosum Associated with Behcet's Disease: Treatment with Thalidomide", <i>J. Am. Acad. Dermatol.</i> , Vol. 23, No. 5, Pt. 1, pp. 941-944 (1990)
NH	Ryan, et al., "Thalidomide to Treat Esophageal Ulcer in AIDS (6)", <i>New Engl. J. Med.</i> , Vol. 327, No. 3, pp. 208-209 (1992)
NI	Salven, P. et al., "Serum Vascular Endothelial Growth Factor Is Often Elevated in Disseminated Cancer", <i>Clinical Cancer Research</i> , Vol. 3, pp. 647-651 (1997)
NJ	Sampaio, et al., "Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum Lepromatous Leprosy Patients", <i>J. Exp. Med.</i> , Vol. 175, No. 6, pp. 1729-1737 (1992)
NK	Sampaio, et al., "Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", <i>J. Exp. Med.</i> , Vol. 173, No. 3, pp. 699-703 (1991)
NL	Santis, H.R., "Aphthous Stomatitis and its Management", <i>Curr. Opin. Dent.</i> , Vol. 1, No. 6, pp. 763-768 (1991) (Abstract Only)
NM	Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", <i>Clin. Immunol. Immunopathol.</i> , Vol. 67, No. 3 I, pp. 199-203 (1993)
NN	Sato, K. et al., "Increased Concentration of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Cyst Fluid of Enlarging and Recurrent Thyroid Nodules", <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 82, No. 6, pp. 1968-1972 (1997)
NO	Schweigerer, L. et al., "Angiogenesis and Angiogenesis Inhibitors in Paediatric Diseases", <i>European J. of Pediatric</i> , Vol. 151, pp. 472-476 (1992)
NP	Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", <i>Scand. J. Immunol.</i> , Vol. 13, No. 6, pp. 553-562 (1981)
NQ	Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosus is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", <i>Lepr. Rev.</i> , Vol. 63, No. 1, pp. 5-11 (1992)
NR	Shealy, Y.F. et al., "D-and L-Thalidomide", <i>Chemistry and Industry</i> , pp. 1030-1031 (1965)
NS	Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", <i>Arthritis and Rheuma.</i> , Vol. 29, No. 10, p. 1296 (1986)
NT	Sherman, M. et al., "Thalidomide: A Twenty-Five Year Perspective", <i>Food Drug Cosmetic Law J.</i> , Vol. 41, pp. 458-466 (1986)
NU	Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", <i>Int. J. Dermatol.</i> , Vol. 19, No. 6, pp. 318-322 (1980)
NV	Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", <i>Dermatologica</i> , Vol. 162, No. 2, pp. 86-90 (1981)
NW	Shi, G. et al., "Kringle Domains and Plasmin Denaturation", <i>Biochem. and Biophys. Res. Comm.</i> , Vol. 178, No. 1, pp. 360-368 (1991)
NX	Schumacher, H. et al., "The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species", <i>Brit. J. Pharmacol.</i> , Vol. 25, pp. 338-351 (1965)
NY	Sidky, Y. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses", <i>Canc. Res.</i> , Vol. 47, pp. 5155-5161 (1987)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/545,139
		Filing Date	April 7, 2000
		First Named Inventor	D'Amato et al.
		Group Art Unit	1614
		Examiner Name	J. Goldberg
Sheet 15 of 17		Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

OA	Silverman, W.A., "Medical Inflation", <i>Persp. Biol. Med.</i> , pp. 617-637 (1980)
OB	Smith, et al., "Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds", <i>Chemical Structure and Embryopathy</i> , pp. 194-209, <i>no date</i>
OC	Srivastava, A. et al., "The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness Skin Melanoma", <i>Am. J. Pathol.</i> , Vol. 133, pp. 419-423 (1988) (abstract from MEDLINE: Accession no. 06745734)
OD	Style, A., "Early Diagnosis and Treatment of Leprosy in the United States", <i>American Family Physician</i> , Vol. 52, No. 1, 172-178 (1995)
OE	Sugiura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", <i>GANN</i> , Vol. 55, pp. 57-60 (1964)
OF	Suzuki, H., "The History of Iatrogenic Diseases in Japan", <i>First Department of Internal Medicine, University of Envir. And Occup. Health, Kitakyushu, Japan</i> , pp. 35-40, <i>no date</i>
OG	Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", <i>Lancet</i> , Vol. 2, No. 835, p. 966 (1973)
OH	Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", <i>Folia Histo. Cytochem.</i> , Vol. 16, No. 3, pp. 233-240 (1978)
OI	Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprednisolone and Cyclosporine", <i>Transplantation</i> , Vol. 49, No. 1, p. 20-25 (1990)
OJ	Tanaka, Y. et al., "Vascular Endothelial Growth Factor in Diabetic Retinopathy", <i>The Lancet</i> , Vol. 349, p. 1520 (1997)
OK	Taylor, S. et al., "Protamine is an Inhibitor of Angiogenesis", <i>Nature</i> , Vol. 297, pp. 307-312 (1982)
OL	Teppo, L. et al., "Thalidomide-Type Malformations and Subsequent Osteosarcoma", <i>The Lancet</i> , Vol. II, No. 8034, p. 405 (1977)
OM	"Thalidomide 20 Years On", <i>The Lancet</i> , Vol. II, No. 8245, pp. 510-511 (1981)
ON	"Thalidomide", <i>The Merck Index</i> , 11th ed., p. 1458 (1989)
OO	Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", <i>Lepr. India</i> , Vol. 52, No. 3, pp. 423-428 (1980)
OP	Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", <i>Indian J. Exp. Biol.</i> , Vol. 10, pp. 314-315 (1972)
OQ	Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flaviviridis", <i>Indian J. Exp. Biol.</i> , Vol. 10, pp. 316-317 (1972)
OR	Thomas, L. et al., "Successful Treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide", <i>Archives of Dermatol.</i> , Vol. 129, pp. 1261-1264 (1993)
OS	Torry, R. J. et al., "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis", <i>Am. J. of Reproductive Immunology</i> , Vol. 27, pp. 171-179 (1992)
OT	Traldi, et al., "L'impiego Dell'imide Dell'Acido N'italilglutammico (Thalidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affetti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", <i>Cancro</i> , Vol. 18, pp. 336-341 (1965)
OU	Trautman, J. R., "Treatment of Hansen's Disease", <i>Cutis</i> , Vol. 18, No. 1, 62-65 (1976)
OV	Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", <i>Arch. Dermatol</i> , Vol. 116, No. 5, pp. 571-572 (1980)

EXAMINER


DATE CONSIDERED 8/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/545,139
	Filing Date	April 7, 2000
	First Named Inventor	D'Amato et al.
	Group Art Unit	1614
	Examiner Name	J. Goldberg
Sheet 16 of 17	Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

PA	Vasilescu, et al., "Cercetari Privind Actiunea Talidomidei Asupra Celulelor Cultivate in Vitro", <i>Cerc. Fiziol.</i> , Vol. 13, No. 4, pp. 293-300 (1968)
PB	Verhault, et al., "Combination Oral Antiangiogenic Therapy with Thalidomide and Sulindac Inhibits Tumor Growth in Rabbits", <i>Brit. J. Cancer</i> , Vol. 79, No. 1, pp. 114-118 (1999)
PC	Vicente, T. et al., "In Vitro Activity of Thalidomide Against Mycobacterium avium Complex", <i>Archives of Internal Medicine</i> , Vol. 153, p.334 (1993)
PD	Villa, et al., "Antimytotic Effect of Thalidomide and its Metabolites on the Chick Embryo Blood Cells", <i>Haematol. Latina</i> , Vol. 6, pp. 217-221 (1963)
PE	Villa, et al., "Cytological Effects of Thalidomide", <i>The Lancet</i> , pp. 725 (1963)
PF	Vladutiu, A., "Another Chance for Thalidomide?", <i>The Lancet</i> , Vol. I, No. 7444, pp. 981-982 (1966)
PG	Vogelsang, G. B. et al., "Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease", <i>New England J. of Med.</i> , Vol. 326, pp. 1055-1059 (1992)
PH	Vogelsang, et al., "Therapy of Chronic Graft-v-Host Disease in a Rat Model", <i>Blood</i> , Vol. 74, No. 1, No. 1, pp. 507-511 (1989)
PI	Vogelsang, et al., "Thalidomide Induction of Bone Marrow Transplantation Tolerance", <i>Transplant Proc.</i> , Vol. 19, No. 1, Pt. 3, pp. 2658-2661 (1987)
PJ	Vogelsang, et al., "Treatment and Prevention of Acute Graft-versus-Host Disease with Thalidomide in a Rat Model", <i>Transplantation</i> , Vol. 41, No. 5, pp. 644-647 (1986)
PK	Vogt, B. et al., "Inhibition of Angiogenesis in Kaposi's Sarcoma by Captopril", <i>The Lancet</i> , Vol. 349, p. 1148 (1997)
PL	Waters, M.F. et al., "Treatment of Ulcerative Colitis with Thalidomide", <i>Brit. Med. J.</i> , Vol. 1, No. 6166, pp. 792 (1979)
PM	Waters, M., "Use of Thalidomide in Leprosy", <i>BMJ</i> , Vol. 303, No. 6800, p. 470 (1991)
PN	Waters, M.F., "An Internally-Controlled Double Blind Trial of Thalidomide in Severe Erythema Nodosum Leprosum", <i>Lepro. Rev.</i> , Vol. 42, No. 1, pp. 26-42 (1971)
PO	Weidner, J. et al., "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma", <i>The New England J. of Med.</i> , Vol. 324, No. 1, pp. 1-8 (1991)
PP	Weidner, N. et al., "Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Cancer", <i>Am. J. of Pathol.</i> , Vol. 143, No. 2, pp. 401-409 (1993)
PQ	Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma", <i>J. of Nat. Canc. Inst.</i> , Vol. 84, No. 24, 1875-1887 (1992)
PR	Wesolowski, et al., "Effect of Light on a Murine Model of Retinopathy of Prematurity", <i>Invest. Ophthalmol. & Visual Science</i> , Vol. 33, No. 4, p. 1281 (Abstract only) <i>no date</i>
PS	White, C. W. et al., "Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a", <i>The New England J. of Med.</i> , Vol. 32, No. 18, pp. 1197-1200 (1989)
PT	Williams, K. M., "Enantiomers in Arthritic Disorders", <i>Pharmacol. & Therapeutics</i> , Vol. 46, No. 2, pp. 273-295 (1990)
PU	Williams, et al., "Thalidomide Hypersensitivity in AIDS", <i>Lancet</i> , Vol. 337, pp. 436-437 (1991)
PV	Winkelmann, et al., "Thalidomide Treatment of Prurigo Nodularis", <i>Acta. Derm. Venereol.</i> , Vol. 64, No. 5, pp. 412-417 (1984)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>	Complete if Known	
	Application Number	09/545,139
	Filing Date	April 7, 2000
	First Named Inventor	D'Amato et al.
	Group Art Unit	1614
	Examiner Name	J. Goldberg
Sheet 17 of 17	Attorney Docket Number	05213-0650 43170-219681

U.S. PATENT DOCUMENTS

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

QA	Wood, et al., "The Potential use of Thalidomide in the Therapy of Graft-versus-Host Disease - A Review of Clinical and Laboratory Information", <i>Leuk. Res.</i> , Vol. 14, No. 5, pp. 395-399 (1990)
QB	Woodyatt, P.B., "Thalidomide", <i>The Lancet</i> , p. 750. (1962)
QC	Wulff, et al., "Development of Polyneuropathy During Thalidomide Therapy", <i>Br. J. Dermatol.</i> , Vol. 112, No. 4, pp. 475-480 (1985)
QD	Yazici, et al., "Practical Treatment Recommendations for Pharmacotherapy of Behcet's Syndrome", <i>Drugs</i> , Vol. 42, No. 5, pp. 796-804 (1991)
QE	Yoshimura, T. et al., "Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein (MSP, MST1) Confirms MSP as a Member of the Family of Kringle Proteins and Locates the MSP Gene on Chromosome 3", <i>The J. of Biol. Chem.</i> , Vol. 268, No. 21, pp. 15461-15468 (1993)
QF	Youle, et al., "Treatment of Resistant Aphthous Ulceration with Thalidomide in Patients Positive for HIV Antibody", <i>BMJ</i> , Vol. 298, No. 6671, p. 432 (1989)
QG	Youle, et al., "Thalidomide in Hyperalgesic Pharyngeal Ulceration of AIDS", <i>Lancet</i> , Vol. 335, No. 8705, p. 1591 (1990)
QH	Yue, t. et al., "2-Methoxyestradiol, an Endogenous Estrogen Metabolite, Induces Apoptosis in Endothelial Cells and Inhibits Angiogenesis: Possible Role for Stress-Activated Protein Kinase Signaling Pathway and Fas Expression", <i>Molecular Pharmacology</i> , Vol. 51, pp. 951-962 (1997)
QI	Ziche, M. et al., "Nitric Oxide Synthase Lies Downstream from Vascular Endothelial Growth Factor-induced but Not Basic Fibroblast Growth Factor-Induced Angiogenesis", <i>J. Clin. Invest.</i> , Vol. 99, No. 11, pp. 2625-2634 (1997)
QJ	Zwart, D., "Treatment of Grade II Astrocytoma with Thalidomide", <i>Arzneim.-Forsch.</i> , Vol. 16, No. 12, pp. 1688-1689 (1966)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AUG 6 2001

TECH CENTER 1600/2900